NCT02122770 is a Phase 1 clinical trial of MLN4924 in Advanced Solid Tumors, sponsored by Millennium Pharmaceuticals, Inc..

Who is sponsoring NCT02122770?

NCT02122770 is sponsored by Millennium Pharmaceuticals, Inc..

What drugs are being tested in NCT02122770?

Interventions in NCT02122770: MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel.

What condition does NCT02122770 study?

NCT02122770 studies Advanced Solid Tumors.

Is NCT02122770 still recruiting?

NCT02122770 is currently completed. Last updated 7 January 2019.

Are results published for NCT02122770?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-01-07 · How we verify

NCT02122770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

Completed Phase 1 Results posted Last updated 7 January 2019

What this trial tests

Phase 1 trial testing MLN4924 in Advanced Solid Tumors in 51 participants. Completed in 5 June 2017.

Timeline

1 April 2014

Primary endpoint
5 June 2017

5 June 2017

Quick facts

Lead sponsor	Millennium Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	51
Start date	1 April 2014
Primary completion	5 June 2017
Estimated completion	5 June 2017
Sites	4 locations across United States

Drugs / interventions tested

MLN4924
Fluconazole
Itraconazole — full drug profile →
Docetaxel
Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Millennium Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose administration of itraconazole on the single-dose IV PK of MLN4924.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.
Wang B, Wu L, Chen J, Dong L, et al · · 2021 · cited 900× · PMID 33637672 · DOI 10.1038/s41392-020-00443-w
Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs.
Shelton J, Lu X, Hollenbaugh JA, Cho JH, et al · · 2016 · cited 219× · PMID 27960273 · DOI 10.1021/acs.chemrev.6b00209
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Liu F, Chen J, Li K, Li H, et al · · 2024 · cited 195× · PMID 39048965 · DOI 10.1186/s12943-024-02046-3
PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Banasavadi-Siddegowda YK, Russell L, Frair E, Karkhanis VA, et al · · 2017 · cited 113× · PMID 27292259 · DOI 10.1038/onc.2016.199
Targeting ubiquitination for cancer therapies.
Morrow JK, Lin HK, Sun SC, Zhang S. · · 2015 · cited 91× · PMID 26630263 · DOI 10.4155/fmc.15.148
PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, et al · · 2018 · cited 86× · PMID 29106602 · DOI 10.1093/neuonc/nox206
Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy.
Spano D, Catara G. · · 2023 · cited 49× · PMID 38201233 · DOI 10.3390/cells13010029
The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer.
Pellegrino NE, Guven A, Gray K, Shah P, et al · · 2022 · cited 48× · PMID 35408841 · DOI 10.3390/ijms23073480

Verify or expand the search:

Other trials of MLN4924

Trials testing the same drug.

NCT01862328 — Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in · Phase 1 · completed
NCT01814826 — Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years · Phase 1 · completed
NCT01415765 — MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma · Phase 1, PHASE2 · withdrawn

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Millennium Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT03888534 — Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphob · Phase 1 · withdrawn
NCT04056468 — A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepati · Phase 1 · completed
NCT04454918 — Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metab · Phase 1 · completed
NCT04056455 — A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys · Phase 1 · completed
NCT04091438 — A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02122770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Millennium Pharmaceuticals, Inc.
Last refreshed: 7 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02122770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing